ResultsIQ

ResultsIQ › Latest results › Windlas Biotech Limited

Windlas Biotech Limited Q2 FY26 results press release summary

NSE: WINDLAS · BSE: 543329

Results press release of 6 Nov 2025, summarised by AI from the filing.

Expansion advancing well; on track to commission the facility within FY26.

Key takeaways

  1. Plant 6 Expansion advancing well; on track to commission the facility within FY26.
  2. Verticals Growth driven by balanced contributions across CDMO, Trade Generics and Institutional, and Exports verticals.
  3. IPM volumes IPM Q2 FY26 volume declined 0.2% YoY despite 7.7% value growth.

Original filing on BSE

Windlas Biotech Limited Q1 FY27 results

As filed: Revenue ₹248 cr (+18% year on year), EBITDA ₹26.7 cr (+3% year on year), PAT ₹17.7 cr (−2% year on year), EBITDA margin 10.8% (−162 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹239 cr (+17% year on year), EBITDA ₹25.3 cr (+1% year on year), PAT ₹16.0 cr (0% year on year), EBITDA margin 10.6% (−171 bps). Score 33 of 100, Below trend. Revenue and profit growth were below the company's own trend; EBITDA growth was well below it. EBITDA margin fell 171 bps year on year. Revenue rose ₹35.5 cr on a year ago, more than the ₹32.0 cr it added the year before. Share price after the results: +4.3% in 29 days (Nifty 500: +2.4%).
  • Q3 FY26: Revenue ₹233 cr (+20% year on year), EBITDA ₹24.4 cr (+2% year on year), PAT ₹15.0 cr (−6% year on year), EBITDA margin 10.5% (−185 bps). Score 31 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 185 bps year on year. Profit fell 17% from last quarter. Revenue rose ₹38.1 cr on a year ago, more than the ₹33.0 cr it added the year before. Share price after the results: −11.2% in 29 days (Nifty 500: −4.0%).
  • Q2 FY26: Revenue ₹222 cr (+19% year on year), EBITDA ₹29.0 cr (+26% year on year), PAT ₹18.0 cr (+13% year on year), EBITDA margin 13.1% (+76 bps). Score 54 of 100, In line with trend. Revenue and profit growth were below the company's own trend; EBITDA growth was in line with it. EBITDA margin rose 76 bps year on year. Revenue rose ₹35.0 cr on a year ago, more than the ₹34.0 cr it added the year before. Share price after the results: −16.6% in 29 days (Nifty 500: +1.4%).
  • Q1 FY26: Revenue ₹210 cr (+20% year on year), EBITDA ₹26.0 cr (+30% year on year), PAT ₹18.0 cr (+38% year on year), EBITDA margin 12.4% (+95 bps). Score 64 of 100, In line with trend. Revenue growth was below the company's own trend; EBITDA growth was in line with it; profit growth was above it. EBITDA margin rose 95 bps year on year. Revenue rose ₹35.0 cr on a year ago, more than the ₹30.0 cr it added the year before. Share price after the results: +5.9% in 30 days (Nifty 500: +2.1%).
  • Q4 FY25: Revenue ₹203 cr (+19% year on year), EBITDA ₹25.0 cr (+9% year on year), PAT ₹16.0 cr (−6% year on year), EBITDA margin 12.3% (−114 bps). Score 32 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 114 bps year on year. Revenue rose ₹32.0 cr on a year ago, more than the ₹30.0 cr it added the year before. Share price after the results: −8.9% in 29 days (Nifty 500: +2.0%).
  • Q3 FY25: Revenue ₹195 cr (+20% year on year), EBITDA ₹24.0 cr (+20% year on year), PAT ₹16.0 cr (+7% year on year), EBITDA margin 12.3% (−4 bps). Score 34 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit growth were well below it. EBITDA margin was flat year on year. Revenue rose ₹33.0 cr on a year ago, against ₹42.0 cr the year before.
  • Q2 FY25: Revenue ₹187 cr (+22% year on year), EBITDA ₹23.0 cr (+28% year on year), PAT ₹16.0 cr (+14% year on year), EBITDA margin 12.3% (+53 bps). Score 66 of 100, Above trend. EBITDA margin rose 53 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Windlas Biotech Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.